4 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
HF outcomes in HFrEF ... on GDMT, with or ... HF outcomes in HFrEF ... on GDMT, with or ... visualabstract #table
Oral Antihypertensive Medications - Selection by Comorbidities
Comorbidities: 
 • Stable Angina, HFpEF, HFrEF, AFib, TAA/Marfan, Aortic
Antihypertensive Medications ... HFrEF, AFib, TAA ... Dissection • CKD ... Antihypertensive #Medications ... #pharmacology #table
Guideline-Directed Medical Therapy (GDMT) in HFrEF and CKD

 • Class I pillars of HFrEF GDMT across
) in HFrEF and CKD ... GDMT across the ... diuretics, MRA, SGLT2i ... Chronotropes • Medications ... #CKD #HFrEF #management
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... -4 inhibitors SGLT2 ... Improved outcomes in CKD ... #table #comparison